Erschienen in:
06.02.2023 | Peritoneal Surface Malignancy
Evaluating End Points of the Efficacy of Intraperitoneal Chemotherapy Techniques Including PIPAC
verfasst von:
Kevin M. Sullivan, MD, Mustafa Raoof, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 5/2023
Einloggen, um Zugang zu erhalten
Excerpt
Peritoneal metastases (PM) are challenging to treat, with progressive disease resulting in significant detriments to both quality of life and survival for patients. Currently, two accepted treatment methods for PM are available: systemic chemotherapy and cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC). For patients who are not candidates to receive CRS with or without HIPEC, pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a novel method for delivering repeatable intraperitoneal (IP) chemotherapy as a minimally invasive laparoscopic procedure. …